Danaher Corporation’s DHR portfolio, with 75% recurring revenues and more than a 90% mix in life sciences and diagnostics, appears “incrementally more attractive” amid the currently harsh macro environment, according to RBC Capital Markets.
The Danaher Analyst: Deane Dray upgraded Danaher from Sector Perform to Outperform, while raising the price target from $299 to $310.
The Danaher Thesis: The company is a defensive safe-haven and its relative valuation “presents attractive entry point,” Dray said in the upgrade note.
“This upgrade is also consistent with our sector call to increase defensive exposures,” he added.
Also Read: Why This Tesla Analyst Thinks Worst May Be Behind For The EV Pioneer
“We believe the concerns with Danaher’s looming tough COVID comps are overdone, creating an opportunity to own this high-quality defensive name at a reasonable entry point,” the analyst wrote.
“Danaher’s +$20 billion M&A war chest should provide ample firepower to fill any earnings hole,” Dray further mentioned.
DHR Price Action: Shares of Danaher had risen by 0.44% to $264.97 at the time of publication Wednesday, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
